Document Classification

Section Type: RESULTS

Text: In a randomized, open-label study, compared with teprenone, famotidine of 30 mg prospectively decreased both New York Heart Association functional class (p < 0. 05) and plasma BNP levels (183 + / - 26 pg/ml vs. 285 + / - 41 pg/ml, p < 0. 05) ; this corresponded to decreasing both LVDd (57 + / - 2 mm vs. 64 + / - 2 mm, p < 0. 05) and LVDs (47 + / - 2 mm vs. 55 + / - 2 mm, p < 0. 05) with unaltered FS (15 + / - 1 % vs. 17 + / - 1 %).